Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 4/20 | 0.42 |
| ▸ | EZH1 | Q92800 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 8/20 | 0.38 |
| ▸ | HTR4 | Q13639 | 8/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 4/20 | 0.36 |
| ▸ | CCR3 | P51677 | 4/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23823096 | 1.00 | EZH2 (0.42) | EZH2EZH1ACHEHTR4NOTUM | |
| SCHEMBL26881634 | 0.96 | EZH2 (0.41) | EZH2EZH1ACHEHTR4HRH1 | |
| SCHEMBL26881703 | 0.94 | EZH2 (0.40) | EZH2EZH1ACHEHTR4HRH1 | |
| SCHEMBL26881641 | 0.93 | EZH2 (0.41) | EZH2EZH1ACHEHTR4NOTUM | |
| SCHEMBL23823299 | 0.92 | EZH2 (0.42) | EZH2EZH1ACHEHTR4NOTUM | |
| SCHEMBL23823260 | 0.91 | EZH2 (0.40) | EZH2EZH1ACHEHTR4HRH1 | |
| SCHEMBL26683183 | 0.90 | EZH2 (0.39) | EZH2EZH1ACHEHTR4HRH1 | |
| SCHEMBL23823100 | 0.89 | EZH2 (0.42) | EZH2EZH1ACHEHTR4SIGMAR1 | |
| SCHEMBL23823095 | 0.89 | EZH2 (0.42) | EZH2EZH1ACHEHTR4SIGMAR1 | |
| SCHEMBL26683134 | 0.89 | EZH2 (0.42) | EZH2EZH1NOTUMHRH1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365541-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230365541-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| WO-2021180235-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | 四川海思科制药有限公司 | 2021-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365541-A1 | INHIBITOR OF ENHANCER OF ZESTE HOMOLOGUE 2, AND USE THEREOF | EZH2, BMI1, EZH1 | EZH2 1/4885EZH1 3/4885ACHE 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.